What the company does
Prestige BioPharma develops biosimilars, lower-cost versions of complex biological medicines that have already been approved, targeting cancers and autoimmune diseases, and supplies them to healthcare markets globally.
It is listed on KOSPI, South Korea's main stock exchange. Its most advanced product, a biosimilar of the breast-cancer drug Herceptin marketed as Tuznue, has received full European Union approval and is preparing for launch there, while a second biosimilar of the cancer drug Avastin is in late-stage global clinical trials.
Summary is AI-generated and may contain errors · figures from DART filings
Financials
Source: DART · FY ending Dec · latest FY2025Revenue
- FY2023US$88.7
- FY2024US$374.7
- FY2025US$7.4K
Operating profit
- FY2023−US$38.1K
- FY2024−US$34.1K
- FY2025−US$34.8K
Net income
- FY2023−US$1.6K
- FY2024−US$30K
- FY2025US$2.2K
Key ratios (FY2025)
Why it matters · Context, not a recommendation
The company operates as a pharmaceutical group that integrates research, development, and contract manufacturing through two subsidiaries, Prestige BioPharma and Prestige Biologics, providing an in-house, end-to-end service model.
Filings
All disclosures · English when translatedPrice charts coming soon
Interactive price history isn't here yet. Would you use it?